Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLICROSS Trial: Crossover Analysis of Risk Factor Control and Antiaggregation with Polypill (Trinomia)
2021-000982-33Phase 4Active
- Sponsor
- FINBA
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of acetylsalicylic acid + atorvastatin + ramipril in acute coronary syndrome (ACS), coronary arteriosclerosis and cardiac risk factors (2 arms), sponsored by FINBA. Primary endpoints: Systolic blood pressure level and LDL-cholesterol. Started Feb 2022; status: active.
02
Drugs
acetylsalicylic acid + atorvastatin + ramipril
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosiscardiac risk factors
Beyond the preview
Go deeper on 2021-000982-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000982-33.